Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings

PLX·Reported May 13, 2026·Before market open

Protalix BioTherapeutics, Inc. reported Q1 2026 revenue of $33.8M (+233.7% YoY), beat analyst consensus of $11.5M by $22.3M. Diluted EPS came in at $0.22, beat the $-0.01 consensus by $0.23.

Revenue
$33.8Mbeat by $22.3M
Consensus: $11.5M
Diluted EPS
$0.22beat by $0.23
Consensus: $-0.01
SEC

SEC Filings

Earnings release8-K · 0001104659-26-059749
Quarterly report10-Q · 0001104659-26-059756

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Protalix BioTherapeutics, Inc.'s Q1 2026 earnings report.

Protalix BioTherapeutics, Inc. (PLX) reported Q1 2026 earnings on May 13, 2026 before market open.

Protalix BioTherapeutics, Inc. reported revenue of $33.8M and diluted EPS of $0.22 for Q1 2026.

Revenue beat the consensus estimate of $11.5M by $22.3M. EPS beat the consensus estimate of $-0.01 by $0.23.

Compared to the same quarter a year prior, revenue grew 233.7% from $10.1M a year earlier.

You can read the 8-K earnings release (0001104659-26-059749) and the 10-Q periodic report (0001104659-26-059756) directly on SEC EDGAR. The filing index links above go to sec.gov.